Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPHRM.L Regulatory News (PHRM)

  • There is currently no data for PHRM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Operational Update

3 Jul 2015 07:00

RNS Number : 0770S
Phorm Corporation Limited
03 July 2015
 

3 July 2015

 

Phorm Corporation Limited

("Phorm" or the "Company)

 

Operational Update

 

Phorm (AIM: PHRM), a leading internet personalisation technology company, announces an unaudited operational and financial update showing further strong growth in the group's revenues and key performance indicators ("KPIs").

 

RUSSIA

 

Key Performance Indicator

2014 Q3

2014 Q4

2015 Q1

2015 Q2

Average of daily unique users (m)

12.5

23.9

31.5

35.5

Total advertising requests (m)

16,625.3

25,437.3

40,343.5

83,018.9

Total advertisements served (m)

126.9

295.5

342.0

393.3

Total revenues (m RUB)

2.0

9.8

15.7

29.0

 

 

The three core components of the Company's business model are users, inventory (advertising requests) and advertising campaigns (advertisements served). These components are put in place sequentially in order to generate revenue.

 

In terms of users in Russia, the Company is delighted to announce that the average daily unique user numbers has grown from 12.5 million in Q3 2014 to 35.5 million in Q2 2015. These figures serve to demonstrate the scale of the opportunity available to the Company.

 

The number of advertising requests to which the Company has access in Russia has also increased significantly. The number of requests has more than doubled from 40.3 billion in Q1 2015 to 83.1 billion Q2 2015. Phorm now has publishing deals in place with some of the largest players in the market and the Company expects this to continue to grow over the coming months.

 

The most important component of the Company's business model is the advertising campaigns. The growth in both advertisements served and revenues provides evidence of the increasing adoption of Phorm's product in the market. Unaudited revenue derived from Russia has almost doubled, from RUB15.7 million (approximately US$0.3 million) in Q1 2015 to RUB29.0 million (approximately US$0.5 million) in Q2 2015. The growth in revenue is based on demonstrating the performance of the platform to the advertisers through a series of paid for test campaigns. Phorm is now working with six of the top tier global agencies in Russia.

 

Phorm is also delighted to announce that, following these results, five of the agencies have agreed to begin integrating Phorm's platform into their trading desks, which is expected to significantly increase the number of campaigns to which Phorm has access. In addition, two of these agencies have already started integration training. The Company is particularly pleased with this development as it provides rapid access to large numbers of campaigns without having to increase the cost base of our Russian operations.

 

United States of America ("US")

 

Key Performance Indicator

2015 Q2

Average of daily unique users (m)

42.4

Total advertising requests (m)

361,331.8

Total advertisements served (m)

65.9

 

 

The Company announced on 21 April 2015 that is had started commercial operations in the US and has been very pleased with the initial reaction it has received in the market.

 

In terms of users, Phorm has been able to build an audience comparatively quickly and, on average, now has access to 42.4 million daily unique users.

 

The Company has placed significant focus on its ability to integrate with third parties, as it is a route to generating significant commercial scale rapidly. The initial results of this strategy can be seen by the number of advertising requests to which the Company has access. In Q2 2015, Phorm had access to 361.3 billion advertising requests, which is four times more than in Russia and achieved in significantly less time.

 

At this stage, the Company is serving both paid and free test campaigns. There are currently eight campaigns running and Phorm is delighted with the way these initial campaigns are performing and is confident that the majority, if not all, of the free test campaigns will convert to paid-for campaigns in the near future. The pipeline of potential opportunities in the US currently stands at over US$0.5 million and the Company expects this to grow rapidly.

 

As in Russia, the Company will be pursuing a strategy of integrating its technology with the trading desks of the major agencies to quickly access large numbers of campaigns.

 

China

 

In China, as the Company announced on 21 April 2015, the focus has been on developing a partnership with a large local player. A number of these discussions are progressing and further announcements will be made as and when appropriate.

 

 

-Ends-

 

For further information please contact:

Phorm Corporation Limited

Andy Croxson (analysts and investors) +44 20 3397 6001

 

UK Investors

Mirabaud Securities LLP (Broker) +44 20 7321 2508

Jason Woollard

Peter Krens

 

Strand Hanson Limited (Nominated Adviser) +44 20 7409 3494

James Harris

Matthew Chandler

James Dance

 

US Investors

Lippert/Heilshorn and Associates (Investor Relations) +1 212 838 3777

John Heilshorn

 

 

About Phorm

 

Phorm is a global personalisation technology company that makes content and advertising more relevant to the consumer. Phorm's innovative platform preserves user privacy and delivers a more interesting online experience.

 

Phorm's industry leading technology enables its ISP partners to offer a new type of online advertising platform and a free consumer internet content feature, ensuring more relevant advertisements and personalised content for opted-in users.

 

Phorm's advertising platform revolutionises current standards of online privacy, fully protecting the identity of consumers. Phorm's solution is completely opt-in. Only those users consenting to the service are profiled and only ever on an anonymous basis.

 

Phorm's partners include leading ISPs, Publishers, Advertising Networks and Advertisers.

 

Phorm, under a predecessor holding company, was admitted to trading on the AIM market of the London Stock Exchange in 2004.

 

For more information, please visit: www.phorm.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCLLLLBEDFZBBQ
Date   Source Headline
19th Jun 20127:00 amRNSAGM Statement
1st Jun 20127:00 amRNSIntention to Re-Domicile
1st Jun 20127:00 amRNS£20m equity fundraising into Phorm China
22nd May 20127:00 amRNSPhorm Announces AGM Notice & Proposed Board Change
21st Mar 20127:00 amRNSAppointment of Nominated Adviser and Joint Broker
5th Mar 20127:00 amRNSTransfer of Shares
1st Mar 20127:00 amRNSTransfer of Shares
28th Dec 20117:00 amRNSDirector Dealing
12th Dec 201110:10 amRNSTransfer of Shares
7th Dec 201110:19 amRNSTransfer of Shares
2nd Dec 20112:02 pmRNSTR-1: Notification of Major Interest in Shares
2nd Dec 201112:16 pmRNSTransfer of Shares
11th Nov 20117:30 amRNSIssue of Equity
4th Nov 20117:30 amRNSIssue of Equity
21st Oct 20113:28 pmRNSIssue of Equity
20th Oct 20114:14 pmRNSTransfer of Shares
7th Oct 20112:00 pmRNSBlock Admission Return
30th Sep 20117:00 amRNSInterim Results for Six Months Ended 30 June 2011
28th Sep 20117:00 amRNSProduct Launch
30th Jun 20117:00 amRNSAnnual Financial Report
8th Apr 201112:00 pmRNSBlock Admission Return
30th Mar 20117:00 amRNSTR-1: Notification of Major Interest in Shares
22nd Mar 20117:00 amRNSPlacing and operating update
2nd Mar 201112:00 pmRNSTransfer of Shares
1st Feb 201110:14 amRNSResult of AGM
6th Jan 20117:15 amRNSOption Grant and Modification
6th Jan 20117:05 amRNSAdvisory Board Appointment - Juan Villalonga
24th Dec 20108:11 amRNSNotice of AGM
17th Dec 20109:11 amRNSIssue of convertible secured loan notes
8th Oct 20105:25 pmRNSBlock Admission Return
30th Sep 20107:00 amRNSInterim results
22nd Sep 20107:00 amRNSUpdate on Commercial Deployment in Brazil
17th Aug 20103:42 pmRNSCorrection re Share Transfer
16th Aug 20103:58 pmRNSShare Transfer
16th Aug 20108:50 amRNSDirectorate Change
30th Jul 20101:00 pmRNSTransfer of Shares
23rd Jul 201011:17 amRNSDirectorate Change
16th Jul 20104:25 pmRNSTransfer of Shares
9th Jul 20107:00 amRNSTransfer of Shares
7th Jul 20104:55 pmRNSDirector/PDMR Shareholding
7th Jul 20102:19 pmRNSPlacing of Shares
30th Jun 20102:17 pmRNSAnnual Report & Accounts Notification
30th Jun 20107:00 amRNSPreliminary Results
28th Jun 20107:00 amRNSNotification of results
8th Jun 20102:05 pmRNSChange in name of Nominated Adviser
30th Apr 20101:08 pmRNSGrant of options
9th Apr 20105:25 pmRNSBlock Admission Return
26th Mar 20107:00 amRNSCommercial Deployment in Brazil
28th Jan 20104:37 pmRNSNotification of Major Interest in Shares
11th Jan 20104:28 pmRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.